Showing results (41-50 of 54) with videos related to
Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2021
Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary MelanomasAlexander N Shoushtari, Walid K Chatila, Arshi Arora, et al.Journal for Immunotherapy of Cancer|October 12, 2021
Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacyBriana Rose Halle, Allison Betof Warner, Farzana Y Zaman, et al.European Journal of Cancer (Oxford, England : 1990)|November 21, 2023
The features and management of acquired resistance to PD1-based therapy in metastatic melanomaAdriana Hepner, Judith M Versluis, Roslyn Wallace, et al.The Lancet. Oncology|May 14, 2021
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort studyInes Pires da Silva, Tasnia Ahmed, Irene L M Reijers, et al.The British Journal of Dermatology|March 16, 2022
Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational studyXue Bai, Alexander N Shoushtari, Allison Betof Warner, et al.Journal for Immunotherapy of Cancer|June 25, 2026
Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanomaJames William Smithy, Allison Betof, Sebastian Klobuch, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2025
Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable MelanomaElizabeth M Burton, Denái R Milton, Michael T Tetzlaff, et al.Cell|March 31, 2023
T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variantsDaniel Hirschhorn, Sadna Budhu, Lukas Kraehenbuehl, et al.Journal for Immunotherapy of Cancer|October 15, 2025
Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitorsLing Zhu, Yee-Ming M Cheung, Cherie Chiang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2021
Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 MonotherapyXue Bai, Jiani Hu, Allison Betof Warner, et al.Pageof 6